| abstract |
Abstract The present invention relates to the usefulness of a sulfated glycosaminoglycan (GAG) selected from the group consisting of heparan sulfate (HS), depolymerised heparan sulfate, dermatan sulfate (DS), depolymerised dermatan sulfate, low molecular weight heparin (LMWH), and depolymerised heparin having an anti-factor Xa activity of 200 IU/mg or less in treatment or prevention of at least one cytokine mediated condition of the endothelial or epithelial linings. |